Leaflet XATRAL SR 10mg prolonged-release tablets

Product code:
W62086003
Quantity:
30
Indicated for:
benign prostatic hyperplasia
Route of administration:
oral
Substance:
alfuzosin (alpha-1 blocker)
ATC
G04CA01 — Genito urinary system and sex hormones | Drugs used in benign prostatic hypertrophy | Alpha-adrenoreceptor antagonists
Alfuzosin is a medication used to treat symptoms associated with benign prostatic hyperplasia (BPH), a condition characterized by an enlarged prostate that can cause difficulty urinating. Alfuzosin belongs to the class of alpha-blockers and works by relaxing the smooth muscles in the prostate and bladder neck, making it easier to urinate.

It is taken orally, usually once daily after a meal, to reduce the risk of side effects. Beneficial effects may be noticed within a few days of starting treatment.

Common side effects include dizziness, fatigue, headache, or orthostatic hypotension (a drop in blood pressure when standing up). Patients are advised to avoid sudden movements to prevent dizziness. Alfuzosin is contraindicated in patients with severe liver impairment or those taking other medications that may interact with it. It should be used as directed by a doctor.

General data about XATRAL SR 10mg

Substance:
alfuzosin
Date of latest medicines list:
01-06-2026
Product code:
W62086003
Concentration:
10mg
Pharmaceutical form:
prolonged-release tablets
Quantity:
30
Product type:
Original
Price:
41.68 RON
Prescription status:
P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.

Marketing authorisation

Manufacturer:
SANOFI WINTHROP INDUSTRIE - FRANTA
Holder:
SANOFI ROMANIA S.R.L. - ROMANIA
Number:
11628/2019/02
Shelf life:
3 years

Concentrations available for alfuzosin

  • 10mg
  • 2.5mg
  • 5mg

Compensation lists for XATRAL SR 10mg Sanofi

B - Sublist B with 50% discount from the reference price

Price
41.68 RON
Copayment
20.84 RON
Patient
20.84 RON